Sarver Heart Center Dedicated to research and the treatment of heart failure.
-
Upload
berniece-greer -
Category
Documents
-
view
213 -
download
1
Transcript of Sarver Heart Center Dedicated to research and the treatment of heart failure.
![Page 1: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/1.jpg)
Sarver Heart Center
Dedicated to research and the treatment of heart failure
![Page 2: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/2.jpg)
Heart FailureHeart Failure
Douglas Larson, Ph.D.Douglas Larson, Ph.D.Sarver Heart CenterSarver Heart Center
![Page 3: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/3.jpg)
Heart FailureOutline
1. Overview
2. Historical aspects
3. Pathophysiology
4. Hemodynamic measurements
5. Neurohumoral Mechanisms
6. Therapeutics
![Page 4: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/4.jpg)
Heart Failure• Heart failure is characterized by depressed
ventricular contractility and impaired relaxation
• Heart failure is a clinical syndrome with many causes
• Heart failure is defined as limited cardiac output to accomplish daily activities
• Heart failure leads to the accumulation of blood in the veins and lymphatics – affecting the lungs, liver, and kidneys.
![Page 5: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/5.jpg)
Epidemiology of Heart Failure in the US
•More deaths from heart failure than from all forms of cancer combined
•4.7 million symptomatic patients; estimated 10 million in 2037
• Incidence: About 550,000 new cases/year
•Prevalence is 1% between the ages of 50 and 59, progressively increasing to >10% over age 80
3.5
4.7
10
0
2
4
6
8
10
12
1991 2000 2037*
Hea
rt F
ailu
re P
atie
nts
in U
S(M
illio
ns)
![Page 6: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/6.jpg)
Heart Failure• Heart failure will affect one in four Americans
and all of these cases involve altered diastolic function (American Heart Assoc).
• Diastolic heart failure has recently been reported to have a mortality rate of 23% during a 3.1 year follow-up with optimized medical therapy (Jones,R.C. J Am Coll.Cardiol.2004).
![Page 7: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/7.jpg)
Survival Curve- Heart Failure
50
100
75
0 52.5
YEARS
% S
urv
ival
DigitalisDiureticsACE inhibitorsBeta blockersSpironolactone
![Page 8: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/8.jpg)
Heart Failure• Most striking, the mortality rate of heart
failure is only exceeded by that of pancreatic cancer (personal communication, Dr. Gregg Fonarow, UCLA).
• Today the heart failure DRG accounts for the highest hospital admission classification in the United States.
![Page 9: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/9.jpg)
Heart Failure
Further Definition
![Page 10: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/10.jpg)
Heart Failure
Systolic DiastolicEjection fraction < 30%
Ejection fraction > 30%
Cardiac Index < 2.4 L/m2
Normal ejection fraction is 60-70%
![Page 11: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/11.jpg)
Heart Failure• Current systolic heart failure therapeutics
affect symptoms, appreciably prolong life expectancy, but are not curative.
• Current diastolic heart failure therapeutics affect symptoms however without reducing mortality rate.
• This suggests a failure in treating the underlying mechanisms.
![Page 12: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/12.jpg)
Dev
elo
pm
ent
of
Hea
rt F
ailu
re• Initiators: Hypertension, aging,
myocardial infarction, viral infection, vavlular dysfunction, diabetes
• Compensatory: myocyte and extracellular matrix remodeling
• Decompensation phase: • Remodeled extracellular matrix collagen,
• Altered calcium cycling protein expression and function,
• Disordered cytoskeletal proteins, and
• Dilated cardiomyopathy (DCM)
![Page 13: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/13.jpg)
Stage AHypertension
CADDiabetes mellitus
Cardiotoxins
Stage BPrevious MI
LV systolic dysfunctionAsymptomatic
valvular disease
Stage CKnown structural
diseaseShortness of breathReduced exercise
tolerance
Stage DSymptoms with
maximal medical therapy
ACC /AHA Guidelines for the Management of Chronic Heart FailureJACC 38;2101-2113:2001
![Page 14: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/14.jpg)
Class NYHA Classification
Class I (Mild)
No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea (shortness of breath).
Class II (Mild)
Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea.
Class III (Moderate)
Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea.
Class IV (Severe)
Unable to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. If any physical activity is undertaken, discomfort is increased.
![Page 15: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/15.jpg)
Question
Heart failure will affect:A.1 in 1000 Americans
B.1 in 100 Americans
C.1 in 20 Americans
D.1 in 4 Americans
![Page 16: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/16.jpg)
Answer
Heart failure will affect:A.1 in 1000 Americans
B.1 in 100 Americans
C.1 in 20 Americans
D.1 in 4 Americans
![Page 17: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/17.jpg)
Heart FailureOutline
1. Overview
2. Historical aspects
3. Pathophysiology
4. Hemodynamic measurements
5. Neurohumoral Mechanisms
6. Therapeutics
![Page 18: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/18.jpg)
Heart Failure
History:
Clinical observations. Two thousand years ago, Hippocratic Corpus first described heart failure patients with what may have been rheumatic valvular disease.
![Page 19: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/19.jpg)
Heart FailureHistory:
Anatomic Pathology. Galen understood that heart failure was associated with enlargement of cardiac muscle but did not understand that the heart was for pumping blood.
Galen believed that the heart was to generate the vital spirit (pneuma) and this forestalled any understanding of the pathophysiology of heart failure for centuries.
![Page 20: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/20.jpg)
Heart Failure
History: Circulatory Physiology. In 1628, William Harvey published De Motu Cordis that identified the failing cardiac pump with dyspnea and edema Flint in the middle of the nineteenth century recognized the progressive clinical deterioration and poor prognosis associated with ventricular dilation and was the first to suggest hypertrophy as an adaptive response to wall stress.
![Page 21: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/21.jpg)
Heart Failure
History:
Cardiac Hemodynamics. In the early years of the twentieth century Starling of England and Wiggers of the United States were able to interpret the pressure and flow abnormalities associated with heart failure.
![Page 22: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/22.jpg)
Heart FailureHistory:
Molecular Biology. A major change in the above paradigm is now occurring due to the unexpected and counter-intuitive adverse effects of inotropes such as dobutamine, phosphodiesterase inhibitors (milrinone), vasodilators including diltiazem and digitalis.
![Page 23: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/23.jpg)
Heart Failure
History:Molecular Biology. Equally unexpected has been the long-term benefits of adrenergic receptor blockers.
These pharmacological experiences demonstrated that heart failure is not just an inotropic and lusitropic disorder.
![Page 24: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/24.jpg)
Heart Failure
History:
Molecular Biology. Today, the major problem in heart failure is now recognized as altered gene expression and immunological mediation of disordered cell growth, and deterioration of the cardiac interstitium.
![Page 25: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/25.jpg)
Question
Which of the following increases the life expectancy of heart failure patients?A. Dobutamine
B. Beta-blockers
C. Digitalis
D. Milrinone
![Page 26: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/26.jpg)
Answer
Which of the following increases the life expectancy of heart failure patients?A. Dobutamine
B. Beta-blockers
C. Digitalis
D. Milrinone
![Page 27: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/27.jpg)
Heart FailureOutline
1. Overview
2. Historical aspects
3. Pathophysiology
4. Hemodynamic measurements
5. Neurohumoral Mechanisms
6. Therapeutics
![Page 28: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/28.jpg)
HEART FAILURE
Mismatch: inflow to output.
![Page 29: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/29.jpg)
A
B
C
A
B
C
Arterial Pressure Tracing
Pressure-volume loops
Normal Restrictive Dilated
Volume
Pre
ssur
e
![Page 30: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/30.jpg)
A
B
C
A
B
C
Arterial Pressure Tracing
Pressure-volume loops
Normal Diastolic HF Systolic HF
Volume
Pre
ssur
e
SVSV
![Page 31: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/31.jpg)
Examples of Common Causes of Heart Failure
• Hypertension
• Aortic Valvular Stenosis
• Viral cardiomyopathy
• Infarction
• Senescence
• Thyrotoxicosis
• Idiopathic
![Page 32: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/32.jpg)
Heart Failure
Etiology:
• Gene mutation
• Single:
• Duchenne’s Musclular Dystrophy
• Familial hypercholesterolemia (FH)
• Multiple
• Genotype
• Environmental
![Page 33: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/33.jpg)
Myocardial infarction (MI)
• MI is recognized as a leading cause of systolic heart failure.
![Page 34: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/34.jpg)
Heart FailureOutline
1. Overview
2. Historical aspects
3. Pathophysiology
4. Hemodynamic measurements
5. Neurohumoral Mechanisms
6. Therapeutics
![Page 35: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/35.jpg)
TIME
Acuteevent
CompensatoryRemodeling
HeartFailure
Co
mp
rom
ised
he
mo
dyn
am
icF
unc
tion
Time Course of Heart Failure
Decompensated
![Page 36: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/36.jpg)
Heart Failure
PRESSURE OVERLOAD
![Page 37: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/37.jpg)
Heart Failure
VOLUME OVERLOAD
![Page 38: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/38.jpg)
Normal Cardiomyocyte
![Page 39: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/39.jpg)
Intercalated disk folding
![Page 40: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/40.jpg)
Intercalated disk folding
![Page 41: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/41.jpg)
Z-band slippage
![Page 42: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/42.jpg)
Z-band slippage
![Page 43: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/43.jpg)
QuestionDecompensated heart failure is:A. The primary event that occurs
subsequent to myocardial injury
B. Is related to myocyte slippage and cardiac dilation
C. Is reversible with beta-blockers
D. Is related to the remodeling of the ventricular geometry to optimize ventricular function.
![Page 44: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/44.jpg)
AnswerDecompensated heart failure is:A. The primary event that occurs
subsequent to myocardial injury
B. Is related to myocyte slippage and cardiac dilation
C. Is reversible with beta-blockers
D. Is related to the remodeling of the ventricular geometry to optimize ventricular function.
![Page 45: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/45.jpg)
Heart FailureOutline
1. Overview
2. Historical aspects
3. Pathophysiology
4. Hemodynamic measurements
5. Neurohumoral Mechanisms
6. Therapeutics
![Page 46: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/46.jpg)
Sympathetic
![Page 47: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/47.jpg)
Pathogenesis of congestive heart failure
• A number of compensatory mechanisms come into play during the development of chronic heart failure in the body's attempt to maintain perfusion pressure and increase cardiac output: • Augmented sympathetic activity
• Sodium and water retention
• Myocardial hypertrophy
• Ventricular dilatation
![Page 48: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/48.jpg)
Specific Neurohumoral Mechanisms
• In most patients with congestive heart failure, the changes in the peripheral circulation (decreased cardiac output) is accompanied by activation of:
• renin-angiotensin system (RAS)
•sympathetic nervous system
•aldosterone.
![Page 49: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/49.jpg)
RASDecrease blood pressureIncreased sympathetic activityDecreased extracellular volume
Juxtaglomerlular cells release renin
Angiotensinogen Angiotensin I Angiotensin II
ACE
Increases blood pressure - vasoconstrictionActs upon the adrenal cortex to release aldosteroneStimulates the release of vasopressin – fluid retentionFacilitates norepinephrine release from nerve endings
Ang II
![Page 50: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/50.jpg)
• Treating hypertension and heart failure with ACE inhibitors (ACEi) and AII receptor antagonists (ARB) can be used to decrease arterial pressure, ventricular afterload, blood volume and hence ventricular preload, as well as inhibit and perhaps reverse cardiac and vascular hypertrophy and pathologic remodeling.
Angiotensin II (Ang II)
![Page 51: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/51.jpg)
Mo
du
lati
on
of
the
RA
S
![Page 52: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/52.jpg)
Sympathetic NS & Heart Failure
• Epinephrine: sympathetic CNS
1, vasoconstriction
2, negative feedback for NE
1, cardiac specific increased function
2, smooth muscle relaxation
• Norepinephrine: powerful stimulator is ATII.
mainly 1,2
*The heart failure state stimulates sympathetic
outflow thus adding to the Ang II effects.
![Page 53: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/53.jpg)
Inotropicagents
Vasodilators
Diuretics
ACE inhibitors
Aldosteroneinhibitors
HF RX
![Page 54: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/54.jpg)
Markers for Heart Failure diagnosis and Prognosis
![Page 55: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/55.jpg)
Markers of Heart Failure• Neurohormonal
• Brain Natriuretic Peptide (BNP)
• Plasma Norepinephrine
• Myocyte Injury and Matrix Remodeling• Troponins
• Matrix metalloproteinases (MMP)
• PIIINP = Pro-Col III cleaved propeptide
• Inflammation• C-reactive protein, IL-6, TNF-• Soluble IL-2 receptor, CD40-CD154
![Page 56: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/56.jpg)
Natriuretic Peptides (ANP and BNP)
BNP/
![Page 57: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/57.jpg)
ANP versus BNP• The Atrial Natriuretic Peptide (ANP) is
highly stimulated during heart failure.• Constitutively secreted by the atria
• Brain Natriuretic Peptide (BNP) • Secreted by ventricles only during heart
failure.Therefore BNP serves as an important
marker of CHF
![Page 58: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/58.jpg)
BNP
• Serum concentrations of BNP parallels the ejection fraction of the left ventricle.
• Therefore it has become a highly reliable serum marker of heart failure and therapeutic efficacy.
![Page 59: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/59.jpg)
BNPandSurvival
Control and heart failurepatients
![Page 60: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/60.jpg)
BNP
Clinica Chimca Acta 306;19-26:2001
BNP versus Ejection Fraction
![Page 61: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/61.jpg)
BNP Levels
• <100 pg/mL no heart failure
• 100-500 pg/mL suggestive of heart failure
• >500 pg/mL high likely-hood of heart failure
![Page 62: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/62.jpg)
BNP Levels
• Drug therapy for chronic heart failure has been reported to reduce plasma BNP levels.ACEi reduce 40%ARB reduce 10%-blockers reduce 60%Aldosterone blockers reduce 55%
![Page 63: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/63.jpg)
Question
Which of the following BNP levels indicates decompensated heart failure?
A.78 pg/mL
B.159 pg/mL
C.373 pg/mL
D.885 pg/mL
![Page 64: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/64.jpg)
Answer
Which of the following BNP levels indicates decompensated heart failure?
A.78 pg/mL
B.159 pg/mL
C.373 pg/mL
D.885 pg/mL
![Page 65: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/65.jpg)
Heart FailureOutline
1. Overview
2. Historical aspects
3. Pathophysiology
4. Hemodynamic measurements
5. Neurohumoral Mechanisms
6. Therapeutics
![Page 66: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/66.jpg)
HF Therapeutics
• Digitalis: increase inotropy • Dobutamine: increase inotropy • Milrinone: increase inotropy• Beta- blockers: decrease
sympathetic outflow• Diuretics – Lasix: diuresis, naturesis• Spironolactone: aldosterone blocker• ACEi and ARB: vasodilation • Nesiritide: diuresis, vasodilation
![Page 67: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/67.jpg)
Heart Failure Therapies
Medical:• Carvedilol (Coreg) is an and blocker.
• Carvedilol is one of the most efficacious medical therapies for heart failure.
• With NYHA II and III patients, it does not significantly change the survival slope.
![Page 68: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/68.jpg)
Effect of Carvedilol ( and blockade) on Progression in Mild or Moderate Heart Failure
1.0
0.8
0.6
00 50 100 150 200 250 300 350 400 0 50 100 150 200 400
MILD (NYHA II) MODERATE (NYHA III)
Carvedilol(n=232)
Carvedilol(n=133)
Placebo(n=134)
Placebo(n=145)
P=.008 P=.019Risk reduction48%
Risk reduction39%
Days Days
1.0
0.8
0.6
Eve
nt-
free
su
rviv
al
0
![Page 69: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/69.jpg)
Nesiritide - Natrecor® • An i.v. recombinant BNP that induces:
• arterial & venous vasodilation,
• increases water and sodium excretion,
• lowers pulmonary capillary wedge pressure & systemic arterial pressures and
• increases cardiac output.
![Page 70: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/70.jpg)
HF Therapeutics• Digitalis:
• Dobutamine: Increased mortality rate
• Milrinone:
• Beta- blockers: decrease heart rate
• Diuretics – Lasix: K+ depletion
• Spironolactone: Interaction w/ other Rx
• ACEi and ARB: Hypotension
• Nesiritide: Increase mortality rateby 80%
![Page 71: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/71.jpg)
Heart Failure Therapies
Medical: NEW• Cardiac
Resynchronization Therapy (CRT) - resynchronizing the activity of the right and left ventricles in patients with heart failure and ventricular dysynchrony.
![Page 72: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/72.jpg)
Heart Failure Therapies
Medical:• Do medical therapies modulate the
cause or survival?
• In general: ACE inhibitors, & blockers, and CRT help symptoms but only marginally prolong life.
![Page 73: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/73.jpg)
IABP = very temporary
![Page 74: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/74.jpg)
SURGERY
Coronary ArteryBypass Graft (CABG) –
Prolongs life
Heart Failure Therapies
![Page 75: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/75.jpg)
SURGERY
Transplantation-Prolongs life~ 10 years
Heart Failure Therapies
![Page 76: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/76.jpg)
VADS andTotal Artificial Heart –Prolongs life
Heart Failure Therapies
![Page 77: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/77.jpg)
HEART FAILURE
• In general, none of these therapeutic approaches actually addresses the underlying mechanisms of heart failure!
• Thus our research is dedicated to defining pathways and techniques that may provide a therapeutic reversal of the heart failure condition.
![Page 78: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/78.jpg)
Our research goal is to show that the immune status accounts for:
50
100
75
0 52.5
YEARS
% S
urv
ival
Survivors
Died
What factors account What factors account for these survivors versusfor these survivors versusthose who do not survive?those who do not survive?
![Page 79: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/79.jpg)
Question
The two leading causes of heart failure are:
A.MI and alcoholic cardiomyopathy
B.Viral and idiopathic
C.Genetic and diabetes
D.Hypertension and aging
![Page 80: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/80.jpg)
Answer
The two leading causes of heart failure are:
A.MI and alcoholic cardiomyopathy
B.Viral and idiopathic
C.Genetic and diabetes
D.Hypertension and aging
![Page 81: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/81.jpg)
Thank You
Questions?Questions?
![Page 82: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/82.jpg)
Adoptive Transfer II
Altered cardiac function can be adoptively transferred through lymphocytes.
![Page 83: Sarver Heart Center Dedicated to research and the treatment of heart failure.](https://reader030.fdocuments.us/reader030/viewer/2022032607/56649ebf5503460f94bc913c/html5/thumbnails/83.jpg)